Journal of medical economicsHumansUnited StatesMedicaidMajor Depressive DisorderMale
Economic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder.
Prakash S Masand, Anita H Clayton, Mousam Parikh, Filmon Haile, Guillaume Germain, Susannah Ripley, Sophie Ma, François Laliberté, Nadia Nabulsi
Published: 202510.1080/13696998.2025.2587412
Abstract
BACKGROUND: Timely initiation of appropriate major depressive disorder (MDD) therapy is crucial. Medicaid-insured patients with MDD have higher healthcare resource utilization (HRU) and costs than commercially insured patients, making this group esse…
Preview only. Read the full abstract at the source